Last checked at 
LONDON (Alliance News) - Medical technology company ANGLE PLC on Monday said results from tests conducted using its Parsortix liquid biopsy system demonstrated its potential for use in metastatic breast cancer.
ANGLE said it believes the data from the studies conducted by the University of Southern California's Norris Comprehensive Cancer Center demonstrates the potential for the Parsortix liquid biopsy system to replace the invasive biopsy.
"These are more highly encouraging results for the use of the Parsortix system this time for an RNA-based clinical application in breast cancer to replace solid metastatic biopsy. This opens the potential of another highly differentiated liquid biopsy application for Parsortix in a key area of medical need, which cannot be addressed by ctDNA, where there is the potential to improve patient care and at the same time reduce healthcare costs," said ANGLE Chief Executive Andrew Newland.
ANGLE shares were down 0.3% to 72.75 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.